Leukocyte adhesion deficiency type 1 with normal expression of CD 11a, CD11b and CD11c

Authors

  • Muhammad Hussain Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan
  • Mustajab Alam Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan
  • Muhammad Zain Arshad Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan
  • Aftab Hassan Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan
  • Maryam Bibi Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan
  • Hina Mushtaq Armed Forces Institute of Pathology (National University of Medical Sciences), Rawalpindi Pakistan

DOI:

https://doi.org/10.55629/pakjpathol.v35i2.817

Abstract

Leukocyte Adhesion Deficiency Type I (LAD-I) is a rare autosomal recessive disorder resulting from ITGB2 gene mutations on long arm of chromosome 21. This mutation disrupts leukocyte migration, causing impaired wound healing, recurrent infections, periodontitis, delayed umbilical cord separation and neutrophilic leukocytosis. Diagnosis involves flow cytometry to assess CD18, CD11a, CD11b, and CD11c surface expression, along with gene mutation analysis. Early detection and management are crucial for those with LAD-I. Here, we present a case of 11 years old male child with recurrent skin infections and diagnosed with rare phenotype of LAD-1 with normal expression of CD11a, CD11b and CD11c. This case improved our understanding of the mild and delayed presentation of Leukocyte Adhesion Deficiency Type 1 (LAD-I) with variable CD marker expression. It highlights the value of using flow cytometry methods to diagnose inborn errors of immunity, highlighting the need for continued study and increased awareness in this area. Increased knowledge of the various phenotypic expressions of LAD-I among medical professionals and researchers could facilitate prompt diagnosis and treatment, ultimately leading to better outcome and improved quality of life in patients.

Keywords: Adhesion molecules, Flow-cytometric analysis, Integrins, Leukocyte adhesion deficiency, Molecular analysis

References

Novoa EA, Kasbekar S, Thrasher AJ, Kohn DB, Sevilla J, Nguyen T, et al. Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. J Allergy Clin Immuno Pract. 2018; 6(4): 1418-20.

DOI: https://doi.org/10.1016/j.jaip.2017.12.008

van de Vijver E, van den Berg TK, Kuijpers TW. Leukocyte adhesion deficiencies. Hematol Clin. 2013; 27(1): 101–16.

Geroldinger-Simić M, Lehner K, Klein G, Sepp N, Jabkowski J. An adult with severe leukocyte adhesion deficiency type 1. JAAD Case Rep. 2022; 19: 1-3.

DOI: https://doi.org/10.1016%2Fj.jdcr.2021.10.031

Das J, Sharma A, Jindal A, Aggarwal V, Rawat A. Leukocyte adhesion defect: Where do we stand circa 2019? Genes Dis. 2020; 7(1): 107-14.

DOI: https://doi.org/10.1016/j.gendis.2019.07.012

Vandendriessche S, Cambier S, Proost P, Marques PE. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front Cell Dev Biol. 2021; 9: 624025.

DOI: https://doi.org/10.3389/fcell.2021.624025

Bashir MM, Hussain M, Ahmad D, Tipu HN. Leukocyte adhesion deficiency type 1 with low expression of cd 11b. J Coll Physicians Surg Pak. 2018; 28(6): S87-s8.

DOI: https://doi.org/10.29271/jcpsp.2018.06.s87

Kambli PM, Bargir UA, Yadav RM, Gupta MR, Dalvi AD, Hule G, et al. Clinical and genetic spectrum of a large cohort of patients with leukocyte adhesion deficiency type 1 and 3: a multicentric study from India. Front Immunol. 2020; 11: 612703.

DOI: https://doi.org/10.3389/fimmu.2020.612703

Wolach B, Gavrieli R, Wolach O, Stauber T, Abuzaitoun O, Kuperman A, et al. Leucocyte adhesion deficiency* - A multicentre national experience. Eur J Clin Invest. 2019; 49(2): e13047. DOI: https://doi.org/10.1111/eci.13047

Downloads

Published

01-07-2024

How to Cite

1.
Hussain M, Alam M, Arshad MZ, Hassan A, Bibi M, Mushtaq H. Leukocyte adhesion deficiency type 1 with normal expression of CD 11a, CD11b and CD11c . Pak J Pathol [Internet]. 2024 Jul. 1 [cited 2024 Oct. 16];35(2):92-4. Available from: https://pakjpath.com/index.php/Pak-J-Pathol/article/view/817